EC
ALLO icon

EntryPoint Capital’s Allogene Therapeutics ALLO Stock Holding History

EntryPoint Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,815
Closed -$133K – 856
2024
Q1 		$133K Sell
29,815
-8,108
-21% -$33.8K 0.12% 274
2023
Q4 		$122K Buy
+37,923
New +$108K 0.12% 278

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EntryPoint Capital's ALLO Position: Q2 2024 in Review

EntryPoint Capital sold out of Allogene Therapeutics (ALLO) in Q2 2024, closing a stake of 29,815 shares — an estimated $133K sold.

EntryPoint Capital first reported a position in ALLO in Q4 2023 and held it in 2 quarters. The position peaked at $133K in Q1 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q2 2024.

  • EntryPoint Capital reported no remaining Allogene Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 29,815 Allogene Therapeutics shares in Q2 2024, an estimated $133K.
  • EntryPoint Capital first reported a position in Allogene Therapeutics in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Allogene Therapeutics position peaked at $133K in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.